Spine Market Dx: Increasing Pain and Instability
Executive Summary
Once considered the high flying segment of the musculoskeletal industry, the spine industry has finally hit a wall as procedure volumes stall, implant prices tumble, and payors push back on authorizing expensive operations for back pain such as spinal fusion. As economic woes heighten, hand in hand with persistent unemployment just as health care and regulatory reforms kick in, many left the North American Spine Society meeting in early October wondering where the bright spots are in this industry.
You may also be interested in...
Motion Is Back In Spine Market
In less than a month, the US Food and Drug Administration (FDA) recently approved three spine PMAs, two for cervical disc replacement devices, and there are two more cervical discs in the queue for near-term PMA approval. All of this activity suggests the $122 million US cervical disc market is about to gear up.
VCF Market: Interest Remains High As Market Share Shifts
Although the spine market appears to be stabilizing to some extent, the vertebral compression fracture market continues to be challenged by reimbursement issues and lingering controversy stemming from the New England Journal of Medicine articles questioning the efficacy of vertebroplasty and vertebral augmentation as a treatment for VCFs.
Beyond INFUSE: Spine Community Searches For Answers, Alternatives
Medtronic's INFUSE bone morphogenetic protein is the only product in the musculoskeletal industry that has changed the bar in terms of bone healing, and it is under fire for complications related to off-label use. As regulators and payors crack down on INFUSE and hospitals restrict access to the product, surgeons are seeking alternatives and there are a number of companies lining up to fill the void